Regeneus was founded in September 2007 by experienced biotechnology innovators to take advantage of the rapid advances in cell-based regenerative medicine, and the opportunity to develop and commercialise innovative adipose-derived cell therapies to treat a range of orthopaedic and other inflammatory diseases in people and animals.

Regeneus is committed to developing its proprietary regenerative cell therapy in order to provide physicians and veterinarians with next generation tools for the treatment of and functional restoration of damaged or diseased tissues. The multi potential use of our regenerative cell products provides the basis for a cell therapy platform that is able to address a wide range of inflammatory conditions.

Our Purpose

To transform our knowledge and research of the regenerative capacities of adipose-derived cells into truly innovative therapies for people and animals.

A future where regenerative medicine plays an integral role in improving the quality of life of people and animals.

At Regeneus, we value:

- Innovation and collaboration

- Commitment to achieving our goals

- Respect for people

- Integrity in our dealings

- Quality in everything we do

Quality

Quality at Regeneus is valued company wide.

Regeneus is committed to implementing and maintaining relevant quality management systems within the company and throughout our licensed partners.

Our quality systems reflect the needs of both Regeneus and its clients.